US 11,207,518 · Application 12/259,208 · Granted Dec 28, 2021
US 11,207,518
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
Estimated expiration
March 29, 2027
192 days remaining
Earliest effective filing
Dec 22, 2005
+ 20 years
Dec 22, 2025
PTA +462d
Mar 29, 2027
No TD
—
Final
Mar 29, 2027
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- October 27, 2008
- Earliest effective filing
- December 22, 2005
- Issue date
- December 28, 2021
- PTA
- +462 days
- Base expiry (before PTA)
- December 22, 2025
December 22, 2005 + 20 years = December 22, 2025 + 462 PTA days = March 29, 2027
- Continuation-in-part of application 11/318,075, filed Dec 22, 2005, issued as US 11,344,724
- PRO60/639,332 — Provisional — not used for base term
- PRO60/639,332 — Provisional — not used for base term
- PRO60/982,681 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 12/259,208 · US 11,207,518
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,207,518: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11207518Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.